Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 76 clinical trials
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity …

plasma cell leukemia
hematologic malignancy
cell transplantation
  • 12 Apr, 2022
  • 1 location
Protocol For Collecting Data On Patients With Childhood Cancer

Progress in the development of curative therapy for pediatric malignancies has resulted in increasing numbers of long-term childhood cancer survivors. This protocol is a means to provide continuing review of outcome and late toxicity for all patients actively being treated and previously treated for childhood cancer at St. Jude Children's …

  • 04 Oct, 2022
  • 1 location
Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study

cancer chemotherapy
stage iii non-small cell lung cancer
stage iv non-small cell lung cancer
lung carcinoma
  • 30 Aug, 2021
  • 5 locations
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory

viremia. Currently, there is no consensus on salvage therapy for patients who remain virus-positive after a second round of antiviral therapy. This is the first multicenter, prospective, parallel

antiviral drugs
  • 29 May, 2022
  • 13 locations
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.

Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance or salvage therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status as well

parp inhibitor
interval debulking surgery
cancer chemotherapy
ovarian epithelial carcinoma
recurrent ovarian cancer
  • 18 Sep, 2022
  • 1 location
Use of Ultrasound Imaging and Spectroscopy as Early Indicators of Locally- Advanced Breast Cancer Response to Neoadjuvant Treatment

This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to cancer treatment and predicting which patients continue on in their …

cancer treatment
advanced breast cancer
measurable disease
breast carcinoma
  • 24 Jan, 2021
  • 1 location